Promising Preliminary Results in Optic Nerve Recovery Study of NurExone Biologic (TSXV: NRX)(OTCQB:NRXBF)(FSE: J90) first product ExoPTEN for Glaucoma Minimally Invasive treatment with ExoPTEN showed functional restoration of damaged eyes to healthy levels in animals Press Release Link: https://lnkd.in/gEbTxigV
About us
Thesis Capital Inc is a leading independent capital markets advisory firm catering to Canadian issuers. We aim to provide objective advice to public and private companies on their investor relations, communications strategy, and overall market intelligence. Our strength lies in our quality relationships with key stakeholders involved in the entire capital markets industry. Whether you are already public or are in the process of going public, Thesis can assist you in navigating through the Canadian capital markets.
- Website
-
http://thesiscapital.ca
External link for Thesis Capital Inc.
- Industry
- Capital Markets
- Company size
- 2-10 employees
- Headquarters
- Toronto, Ontario
- Type
- Privately Held
- Founded
- 2018
- Specialties
- Investor Relations, Corporate Communications, Deal and Non-Deal Roadshows, Market Awareness, and Go Public Strategies
Locations
-
Primary
36 King St E
Toronto, Ontario, CA
Employees at Thesis Capital Inc.
Updates
-
Heritage Mining Ltd. (CSE: HML | FRA: Y66) Reports Successful SGH Orientation Survey Highlights: 🔹The overall precision of the SGH analysis for the samples at the Alcona Area Soil Survey was excellent. Mineralization exists at these locations as a vertical projection beneath these anomalies. 🔹The SGH confidence rating for the Alcona survey assigned to the anomalies averages 5.0 on a scale of 6.0. The rating for the Alcona Orientation Survey results indicates that there is a high probability that gold mineralization is present, thereby supporting a property wide survey. 🔹Predicted Gold Mineralization complemented by Halo anomaly illustrating possible presence of Redox Zone an environment associated with gold mineralization. 🔹Zone 3 SGH Soils results are expected within the next week. Press Release Link: https://lnkd.in/gDtqkWAq
-
Ramp Metals Inc. (TSXV: RAMP) Announces $4.5M Non-Brokered Private Placement Led by Strategic Investor Eric Sprott The Offering is expected to consist of the issue and sale of: 🔹Up to 3,846,153 charity flow-through common shares (the "CFT Shares") at a price of $0.78 per CFT Share for gross proceeds of up to approximately $3,000,000; and 🔹Up to 2,727,272 common shares (the "Common Shares") at a price of $0.55 per Common Share for gross proceeds of up to approximately $1,500,000. The proceeds from the issuance of CFT Shares of the Offering will be used for exploration expenses at the Company's Rottenstone SW property in Saskatchewan. Press Release Link: https://lnkd.in/gXjaNcFn
-
NurExone Biologic (TSXV: NRX)(OTCQB:NRXBF)(FSE: J90) ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market The company is pleased to announce a pre-clinical study to explore the potential of NurExone’s exosome-based therapies in regenerating damaged optic nerves. The study, initiated by renowned ophthalmologist and serial entrepreneur Prof. Michael Belkin from Tel Aviv University's Goldschleger Eye Research Institute, and led by the principal investigators Prof. Ygal Rotenstreich and Dr. Ifat Sher from the Sheba Medical Center Eye Institute, is the latest step in expanding potential clinical indications for Nurexone Biologic's exosome-loaded drugs. Press Release Link: https://lnkd.in/gcz7FhjF
-
Scientists Giving New Hope to People With Spinal Cord Injuries "There is a possibility to give hope to many people who would otherwise be disabled," say directors at NurExone Biologic, a company established to develop and commercialize this innovative technology. Full news: https://lnkd.in/dcvP-a23
-
On Path to First-in-Human Study, NurExone Biologic (TSXV: NRX)(OTCQB:NRXBF)(FSE: J90) Engages Prominent Expert in Biological Drug Development NurExone welcomes Dr. Yona Geffen, as a consultant, to support the Company’s preclinical and clinical activities. Dr. Geffen, who currently serves as Vice President of Research and Development at Gamida Cell Ltd., brings over two decades of extensive experience in leading clinical and drug development in the biotechnology and pharmaceutical industries. Under her leadership, Gamida Cell obtained United States Food and Drug Administration approval for Omisirge®, a groundbreaking stem cell therapy. Press Release Link: https://lnkd.in/gcA3gpm2
-
Global Education Communities Corp. (TSX: GEC | OTCQX: GECSF) Provides Updates on its Corporate Activities 🔹After 2.5 years of litigation for GECC's investments in the Atmosphere project, the trial was completed on May 31, 2024, and the court's decision is expected in the coming weeks. 🔹GEC® Oakridge construction is expected to start in Q4 2024. 🔹GEC® Oakridge has submitted a CMHC loan application for $120M in May, and we expect positive results in June or July, which ties in nicely with the recent decline in the Bank of Canada interest rate and Canada's government bond rates. 🔹Application has been made to double the rezoning height for GEC® Langara via the TOA rezoning legislation, allowing for much higher density and minimal parking requirements. 🔹In September 2023, the federal government announced the GST exemption for all rental project developments, reducing development costs significantly. 🔹Revision of the development plan for GEC® EMC is nearly complete for submission to the City of Surrey. 🔹GEC® Kingsway will come online in July and will be ready for occupancy by September. 🔹GEC® Viva is undergoing renovation which is expected to be completed by September. 🔹Most GEC® operating properties are at near-full capacity. Press Release Link: https://lnkd.in/gZte5YRx #realestate #realestatemarket #educationmarket #housingmarket #studenthousing #Vancouver #BritishColumbia #Canada #rentalcrisis #realestatestocks #educationstocks #microcap #TSX #OTCQX #stocks #stockmarket #stocknews #stockstowatch #stockstobuy #invest #investors #investing #whatsyourthesis
-
NurExone Biologic (TSXV: NRX)(OTCQB:NRXBF)(FSE: J90) Announces Expansion of ExoPTEN Patent Coverage with Notice of Allowance for Japanese Patent Application The patent, titled “Vesicles Comprising a PTEN Inhibitor and Uses of Same”, was originally submitted by the Technion Research and Development Foundation Ltd. (“Technion”) and Ramot at Tel Aviv University Ltd. It is the first patent licensed by NurExone from Technion and describes a fundamental element of the Company’s ExoPTEN nanodrug under development for acute spinal cord injury. Press Release Link: https://lnkd.in/gSWKVAJa #lifescience #healthcare #biotech #medtech #spinalcordinjury #spinalinjury #braininjury #traumaticbraininjury #technology #medicine #treatment #therapeutics #drugdiscovery #stock #investing #investor #stockmarket #stockstowatch #whatsyourthesis
-
Litchfield Hills Research provides an update on NurExone Biologic (TSXV: NRX)(OTCQB:NRXBF)(FSE: J90) and reiterates its buy rating and price target of $4.00/share. Key Highlights: 🔹NurExone exceeded Q1 2024 expectations by reporting an EPS loss of $0.016 versus loss estimate of $0.022. 🔹Shares appear to be priced below absolute and comparative metrics based on discounted future earnings. 🔹Expanded preclinical testing: Contract Research Organization services agreement with Vivox Ltd. for animal experiments. 🔹Lab expansion: NurExone executed a lease for lab space with the Technion. 🔹Key hire in licensing efforts: NurExone hired Dr. Ram Petter, Ph.D., MBA, as a consultant. 🔹Broadening market reach in the United States: NurExone received listing approval on the OTCQB and DTC eligibility under the symbol (OTCQB: NRXBF). 🔹Revision to estimate: With the higher share count, NurExone's EPS losses for 2024 and 2025 decline to $0.08 from a loss of $0.09. Click the attachment below to read the full report. #lifescience #healthcare #biotech #medtech #spinalcordinjury #spinalinjury #braininjury #traumaticbraininjury #technology #medicine #treatment #therapeutics #drugdiscovery #stock #investing #investor #stockmarket #stockstowatch #whatsyourthesis